RESUMO
Alzheimer′s disease is a progressive neurodegenerative disease that requires medication to improve patient symptoms, but there is an individual difference in the efficacy. In this paper, the correlation between single nucleotide polymorphism and the drug efficacy of Alzheimer′s disease (AD) in the past 20 years was searched through the databases of China National Knowledge Infrastructure, VIP Database, Wanfang Database, Pubmed, Springer Link and Cochrane Library with key words of Alzheimer′s disease, drug efficacy, single nucleotide polymorphism. The correlation between AD drug efficacy difference and gene single nucleotide polymorphism was reviewed, including ABCA1, ApoE, ChAT, CHRNA7, IL-6, A2M, CYP2D6, BChE, 5HT2a, PON-1 and ESR1 genes, so as to provide a reference basis for clinicians to select drugs in the treatment of AD.
RESUMO
Early diagnosis is the key to improve the prognosis of gastric cancer. How to screen out high-risk subjects of gastric cancer in population is a hot spot. Serum-based early detection of gastric cancer is suitable for high-risk population screening, which is more convenient and safer. This article reviews the diagnostic value of serum biomarkers for gastric cancer, including serum DNA methylation, various RNAs, pepsinogen, gastrin, osteopontin, MG7-Ag and CA724. Until now, there is still lack of ideal biomarkers for gastric cancer, and searching for specific RNAs may be promising for early diagnosis and screening of gastric cancer.
Assuntos
Humanos , Biomarcadores Tumorais , Sangue , Detecção Precoce de Câncer , Sensibilidade e Especificidade , Neoplasias Gástricas , Sangue , DiagnósticoRESUMO
Objective To observe and analyze the clinical efficacy of amitriptyline combined with domperidone in the treatment of functional dyspepsia ( FD) .Methods 156 patients with FD were selected as the study subjects , and they were randomly divided into the observation group and the control group ,78 cases in each group .The patients in the control group were treated with domperidone ,and the patients in the observation group were given amitriptyline combined with domperidone .The changes of clinical symptoms scores and the occurrence of adverse reactions were observed before and after treatment in both two groups ,and the clinical curative effect was compared .Results After treatment,the total effective rate of the observation group was 93.59％,which was significantly higher than 76.92％of the control group,and there was significant difference between the two groups (χ2 =10.59,P<0.01).The early satiety,postprandial bloating,nausea and vomiting,epigastric distending pain,belching and other clinical symptoms scores in two groups were significantly reduced ( tobservation group =21.95,33.78,42.12,37.58,42.64, tcontrol group =17.54,8.88,16.43,10.98,15.06,all P<0.01),and the clinical symptoms of the observation group improved more significantly (t=9.89,9.79,8.47,9.99,18.52,all P<0.01).The incidence rate of adverse reactions in the obser-vation group was 16.67％,which in the control group was 23.08％,the difference between the two groups was not statistically significant (χ2 =1.09,P>0.05).After the treatment,the adverse reactions disappeared spontaneously . Conclusion Compared with the use of domperidone alone , the clinical efficacy of amitriptyline combined with domperidone in the treatment of FD patients is significant with good safety ,and is conducive to improve the clinical symptoms of patients ,increase the efficacy and worthy of clinical application .
RESUMO
Tanshinone Ⅱ A is effective to treat a great variety of diseases,and recently its potential anticancer activity has attracted great attention.While studies in vitro indicate that tanshinone Ⅱ A is toxic in a number of cell types and affects differentiation and apoptosis,but anticancer effects in vivo remain to be elucidated.Tanshinone Ⅱ A varies widely in production quality,method of administration (oral,intravenous,subcutaneous,and so on),usage and dosage.Tanshinone Ⅱ A s limited hydrophilicity,poor intestinal absorption,low oral efficacy,and other pharmacologic characteristics have impacted both its usage and elucidation of efficacy and mechanisms in vivo,which are the focus of future research.
RESUMO
ObjectiveTo study the efficacy of adjuvant percutaneous transhepatic portal vein chemoembolization (PVCE) in the prevention of tumor recurrence after partial hepatectomy for hepatocellular carcinoma.MethodsThe clinical data of 89 patients who received liver resection for hepatocellular carcinoma in our hospital from January 2007 to January 2010 were studied retrospectively.41patients received PVCE (the treatment group) while 48 patients received no PVCE (the control group).Postoperative recurrence and cumulative disease free survivals were compared using the Kaplan-Meier method.ResultsOn follow-up which ranged from 6-42 months,the 1- and 2-year disease free survivals were 76.5％ and 48.0％ in the treatment group,and 53.8％ and 25.8％ respectively in the control group (P＜0.05).The mean disease free survivals were 19.91 (95％ CI,16.09-23.73)and 13.8 months (95 ％ CI,10.95-16.65),respectively.The cumulative disease free survivals in the PVCE group were significantly higher than the control group (P=0.01).Cox multivariate analysis showed that adjuvant PVCE,tumor size,portal vein thrombosis,and postoperative transcatheter arterial chemoembolization (TACE) were independent factors of disease free survival.ConclusionAdjuvant PVCE was effective in preventing postoperative recurrence of hepatocellular carcinoma after partial hepatectomy.